To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of
gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform
for the development of novel effective cancer immunotherapies. Advances in non-viral gene …

Ribonucleic acid (RNA)-based therapies have become an attractive topic in disease
intervention, especially with some that have been approved by the FDA such as the mRNA …

Nucleic acid therapeutics are rapidly expanding because of recent advancements in
production and purification. This class of therapeutics may change the field of disease …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

RNA-based therapeutics have shown great promise in various medical applications,
including cancers, infectious diseases, and metabolic diseases. The recent success of …